APO Research
Talk to an analyst

APO RESEARCH · REPORT

Obsessive-Compulsive Disorder Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Obsessive-Compulsive Disorder Drugs Market Outlook and Growth Opportunities 2026

22 December 2025190 pages

Choose your research edition.

Industry ResearchObsessive-Compulsive Disorder Drugs Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Obsessive-Compulsive Disorder Drugs Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Obsessive-Compulsive Disorder Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Obsessive-Compulsive Disorder Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Obsessive-Compulsive Disorder Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Obsessive-Compulsive Disorder Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Obsessive-Compulsive Disorder Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Obsessive-Compulsive Disorder Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Obsessive-Compulsive Disorder Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Obsessive-Compulsive Disorder Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Obsessive-Compulsive Disorder Drugs market include H. Lundbeck AS, GlaxoSmithKline Plc, Pfizer Inc., Eli Lilly and Co. and Novartis AG, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Obsessive-Compulsive Disorder Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Obsessive-Compulsive Disorder Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Obsessive-Compulsive Disorder Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Obsessive-Compulsive Disorder Drugs market.

Obsessive-Compulsive Disorder Drugs Segment by Company

H. Lundbeck AS

GlaxoSmithKline Plc

Pfizer Inc.

Eli Lilly and Co.

Novartis AG

Obsessive-Compulsive Disorder Drugs Segment by Type

SSRI

TCA

Others

Obsessive-Compulsive Disorder Drugs Segment by Application

Clinic

Hospital

Research Institute

Other

Obsessive-Compulsive Disorder Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Obsessive-Compulsive Disorder Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Obsessive-Compulsive Disorder Drugs key companies, revenue, market share, and recent developments.

3. To split the Obsessive-Compulsive Disorder Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Obsessive-Compulsive Disorder Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Obsessive-Compulsive Disorder Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Obsessive-Compulsive Disorder Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Obsessive-Compulsive Disorder Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Obsessive-Compulsive Disorder Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Obsessive-Compulsive Disorder Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Obsessive-Compulsive Disorder Drugs industry.

Chapter 3: Detailed analysis of Obsessive-Compulsive Disorder Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Obsessive-Compulsive Disorder Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Obsessive-Compulsive Disorder Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Obsessive-Compulsive Disorder Drugs Industry Trends Table 2. Obsessive-Compulsive Disorder Drugs Industry Drivers Table 3. Obsessive-Compulsive Disorder Drugs Industry Opportunities and Challenges Table 4. Obsessive-Compulsive Disorder Drugs Industry Restraints Table 5. Global Obsessive-Compulsive Disorder Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Obsessive-Compulsive Disorder Drugs Revenue Share by Company (2021-2026) Table 7. Global Obsessive-Compulsive Disorder Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Obsessive-Compulsive Disorder Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Obsessive-Compulsive Disorder Drugs Company, Product Type & Application Table 10. Global Obsessive-Compulsive Disorder Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Obsessive-Compulsive Disorder Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of SSRI Table 15. Significant Companies of TCA Table 16. Significant Companies of Others Table 17. Global Obsessive-Compulsive Disorder Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Obsessive-Compulsive Disorder Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Obsessive-Compulsive Disorder Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Obsessive-Compulsive Disorder Drugs Sales Value Share by Type (2021-2026) Table 21. Global Obsessive-Compulsive Disorder Drugs Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Clinic Table 23. Significant Companies of Hospital Table 24. Significant Companies of Research Institute Table 25. Significant Companies of Other Table 26. Global Obsessive-Compulsive Disorder Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Obsessive-Compulsive Disorder Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Obsessive-Compulsive Disorder Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Obsessive-Compulsive Disorder Drugs Sales Value Share by Application (2021-2026) Table 30. Global Obsessive-Compulsive Disorder Drugs Sales Value Share by Application (2027-2032) Table 31. Global Obsessive-Compulsive Disorder Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Obsessive-Compulsive Disorder Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Obsessive-Compulsive Disorder Drugs Sales Value Share by Region (2021-2026) Table 34. Global Obsessive-Compulsive Disorder Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Obsessive-Compulsive Disorder Drugs Sales Value Share by Region (2027-2032) Table 36. Global Obsessive-Compulsive Disorder Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Obsessive-Compulsive Disorder Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Obsessive-Compulsive Disorder Drugs Sales Value Market Share by Country (2021-2026) Table 39. Global Obsessive-Compulsive Disorder Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Obsessive-Compulsive Disorder Drugs Sales Value Market Share by Country (2027-2032) Table 41. H. Lundbeck AS Company Information Table 42. H. Lundbeck AS Business Overview Table 43. H. Lundbeck AS Obsessive-Compulsive Disorder Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. H. Lundbeck AS Obsessive-Compulsive Disorder Drugs Product Portfolio Table 45. H. Lundbeck AS Recent Development Table 46. GlaxoSmithKline Plc Company Information Table 47. GlaxoSmithKline Plc Business Overview Table 48. GlaxoSmithKline Plc Obsessive-Compulsive Disorder Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. GlaxoSmithKline Plc Obsessive-Compulsive Disorder Drugs Product Portfolio Table 50. GlaxoSmithKline Plc Recent Development Table 51. Pfizer Inc. Company Information Table 52. Pfizer Inc. Business Overview Table 53. Pfizer Inc. Obsessive-Compulsive Disorder Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Pfizer Inc. Obsessive-Compulsive Disorder Drugs Product Portfolio Table 55. Pfizer Inc. Recent Development Table 56. Eli Lilly and Co. Company Information Table 57. Eli Lilly and Co. Business Overview Table 58. Eli Lilly and Co. Obsessive-Compulsive Disorder Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Eli Lilly and Co. Obsessive-Compulsive Disorder Drugs Product Portfolio Table 60. Eli Lilly and Co. Recent Development Table 61. Novartis AG Company Information Table 62. Novartis AG Business Overview Table 63. Novartis AG Obsessive-Compulsive Disorder Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Novartis AG Obsessive-Compulsive Disorder Drugs Product Portfolio Table 65. Novartis AG Recent Development Table 66. Research Programs/Design for This Report Table 67. Authors List of This Report Table 68. Secondary Sources Table 69. Primary Sources List of Figures Figure 1. Obsessive-Compulsive Disorder Drugs Product Image Figure 2. Global Obsessive-Compulsive Disorder Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Obsessive-Compulsive Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Obsessive-Compulsive Disorder Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. SSRI Image Figure 8. TCA Image Figure 9. Others Image Figure 10. Global Obsessive-Compulsive Disorder Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Obsessive-Compulsive Disorder Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Obsessive-Compulsive Disorder Drugs Sales Value Share by Type (2021-2032) Figure 13. Clinic Image Figure 14. Hospital Image Figure 15. Research Institute Image Figure 16. Other Image Figure 17. Global Obsessive-Compulsive Disorder Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Obsessive-Compulsive Disorder Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Obsessive-Compulsive Disorder Drugs Sales Value Share by Application (2021-2032) Figure 20. Global Obsessive-Compulsive Disorder Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Obsessive-Compulsive Disorder Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Obsessive-Compulsive Disorder Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. North America Obsessive-Compulsive Disorder Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Obsessive-Compulsive Disorder Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Obsessive-Compulsive Disorder Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Obsessive-Compulsive Disorder Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Obsessive-Compulsive Disorder Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Obsessive-Compulsive Disorder Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. South America Obsessive-Compulsive Disorder Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Obsessive-Compulsive Disorder Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Obsessive-Compulsive Disorder Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • SSRI
  • TCA
  • Others
Applications
  • Clinic
  • Hospital
  • Research Institute
  • Other
Companies covered
  • H. Lundbeck AS
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Eli Lilly and Co.
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Obsessive-Compulsive Disorder Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Obsessive-Compulsive Disorder Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Obsessive-Compulsive Disorder Drugs Market Dynamics
  1. 2.1 Obsessive-Compulsive Disorder Drugs Industry Trends
  2. 2.2 Obsessive-Compulsive Disorder Drugs Industry Drivers
  3. 2.3 Obsessive-Compulsive Disorder Drugs Industry Opportunities and Challenges
  4. 2.4 Obsessive-Compulsive Disorder Drugs Industry Restraints
3 Obsessive-Compulsive Disorder Drugs Market by Company
  1. 3.1 Global Obsessive-Compulsive Disorder Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Obsessive-Compulsive Disorder Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Obsessive-Compulsive Disorder Drugs Company Ranking (2024-2026)
  4. 3.4 Global Obsessive-Compulsive Disorder Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Obsessive-Compulsive Disorder Drugs Company Product Type and Application
  6. 3.6 Global Obsessive-Compulsive Disorder Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Obsessive-Compulsive Disorder Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Obsessive-Compulsive Disorder Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Obsessive-Compulsive Disorder Drugs Market by Type
  1. 4.1 Obsessive-Compulsive Disorder Drugs Type Introduction
  2. 4.1.1 SSRI
  3. 4.1.2 TCA
  4. 4.1.3 Others
  5. 4.2 Global Obsessive-Compulsive Disorder Drugs Sales Value by Type
  6. 4.2.1 Global Obsessive-Compulsive Disorder Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Obsessive-Compulsive Disorder Drugs Sales Value by Type (2021-2032)
  8. 4.2.3 Global Obsessive-Compulsive Disorder Drugs Sales Value Share by Type (2021-2032)
5 Obsessive-Compulsive Disorder Drugs Market by Application
  1. 5.1 Obsessive-Compulsive Disorder Drugs Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Research Institute
  5. 5.1.4 Other
  6. 5.2 Global Obsessive-Compulsive Disorder Drugs Sales Value by Application
  7. 5.2.1 Global Obsessive-Compulsive Disorder Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Obsessive-Compulsive Disorder Drugs Sales Value by Application (2021-2032)
  9. 5.2.3 Global Obsessive-Compulsive Disorder Drugs Sales Value Share by Application (2021-2032)
6 Obsessive-Compulsive Disorder Drugs Regional Value Analysis
  1. 6.1 Global Obsessive-Compulsive Disorder Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Obsessive-Compulsive Disorder Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Obsessive-Compulsive Disorder Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Obsessive-Compulsive Disorder Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Obsessive-Compulsive Disorder Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Obsessive-Compulsive Disorder Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Obsessive-Compulsive Disorder Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Obsessive-Compulsive Disorder Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Obsessive-Compulsive Disorder Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Obsessive-Compulsive Disorder Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Obsessive-Compulsive Disorder Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Obsessive-Compulsive Disorder Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Obsessive-Compulsive Disorder Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Obsessive-Compulsive Disorder Drugs Sales Value Share by Country, 2025 VS 2032
7 Obsessive-Compulsive Disorder Drugs Country-level Value Analysis
  1. 7.1 Global Obsessive-Compulsive Disorder Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Obsessive-Compulsive Disorder Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Obsessive-Compulsive Disorder Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Obsessive-Compulsive Disorder Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Obsessive-Compulsive Disorder Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Obsessive-Compulsive Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Obsessive-Compulsive Disorder Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 H. Lundbeck AS
  2. 8.1.1 H. Lundbeck AS Company Information
  3. 8.1.2 H. Lundbeck AS Business Overview
  4. 8.1.3 H. Lundbeck AS Obsessive-Compulsive Disorder Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 H. Lundbeck AS Obsessive-Compulsive Disorder Drugs Product Portfolio
  6. 8.1.5 H. Lundbeck AS Recent Developments
  7. 8.2 GlaxoSmithKline Plc
  8. 8.2.1 GlaxoSmithKline Plc Company Information
  9. 8.2.2 GlaxoSmithKline Plc Business Overview
  10. 8.2.3 GlaxoSmithKline Plc Obsessive-Compulsive Disorder Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Plc Obsessive-Compulsive Disorder Drugs Product Portfolio
  12. 8.2.5 GlaxoSmithKline Plc Recent Developments
  13. 8.3 Pfizer Inc.
  14. 8.3.1 Pfizer Inc. Company Information
  15. 8.3.2 Pfizer Inc. Business Overview
  16. 8.3.3 Pfizer Inc. Obsessive-Compulsive Disorder Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Inc. Obsessive-Compulsive Disorder Drugs Product Portfolio
  18. 8.3.5 Pfizer Inc. Recent Developments
  19. 8.4 Eli Lilly and Co.
  20. 8.4.1 Eli Lilly and Co. Company Information
  21. 8.4.2 Eli Lilly and Co. Business Overview
  22. 8.4.3 Eli Lilly and Co. Obsessive-Compulsive Disorder Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly and Co. Obsessive-Compulsive Disorder Drugs Product Portfolio
  24. 8.4.5 Eli Lilly and Co. Recent Developments
  25. 8.5 Novartis AG
  26. 8.5.1 Novartis AG Company Information
  27. 8.5.2 Novartis AG Business Overview
  28. 8.5.3 Novartis AG Obsessive-Compulsive Disorder Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis AG Obsessive-Compulsive Disorder Drugs Product Portfolio
  30. 8.5.5 Novartis AG Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst